{"prompt": "['2016N277425_0', 'CONFIDENTIAL', '2018N377698_00', '201749', 'mcg', 'Microgram', 'MCID', 'Minimal Clinically Important Difference', 'MDI', 'Metered Dose Inhaler', 'mL', 'Milliliter', 'mMRC', 'Modified Medical Research Council', 'MMRM', 'Mixed Models Repeated Measures', 'MSDS', 'Material Safety Data Sheet', 'NYHA', 'New York Heart Association', 'OTC', 'Over the Counter', 'PGx', 'Pharmacogenetic', 'PIL', 'Patient Information Leaflet', 'PK', 'Pharmacokinetic', 'PP', 'Per Protocol', 'prn', 'As required', 'QTc', 'QT interval corrected for heart rate', 'RAP', 'Reporting and Analysis Plan', 'SABA Short Acting Beta-Agonist', 'SAE', 'Serious Adverse Event', 'SD', 'Standard Deviation', 'SmPC', 'Summary of Product Characteristics', 'SRT', 'Safety Review Team', 'TDI', 'Transition Dyspnea Index', 'RAMOS NG', 'Randomization and medication ordering system new', 'generation', 'ULN', 'Upper Limit of Normal', 'UMEC', 'Umeclidinium (GSK573719)', 'UMEC/VI', 'Umeclidinium & Vilanterol as a fixed dose combination', 'VI', 'Vilanterol Trifenate', 'Trademark Information', 'Trademarks of the GlaxoSmithKline', 'Trademarks not owned by the', 'group of companies', 'GlaxoSmithKline group of companies', 'ANORO', 'E-RS', 'DISKUS', 'EXCACT', 'ELLIPTA', 'INCRUSE', 'SEREVENT', '69']['2016N277425_0', 'CONFIDENTIAL', '2018N377698_00', '201749', '12.2.', 'Appendix 2: Liver Safety Required Actions and Follow up', 'Assessments', 'Phase III-IV liver chemistry stopping criteria and required follow up assessments', 'Liver Chemistry Stopping Criteria - Liver Stopping Event', 'ALT-absolute', 'ALT 8xULN', 'ALT Increase', 'ALT 5xULN but <8xULN persists for >2 weeks', 'ALT 3xULN but <5xULN persists for >4 weeks', 'Bilirubin1, 2', 'ALT > 3xULN and bilirubin > 2xULN (>35% direct bilirubin)', 'INR\u00b2', 'ALT > 3xULN and INR>1.5, if INR measured', 'Cannot', 'ALT 5xULN but <8xULN and cannot be monitored weekly for >2 weeks', 'Monitor', 'ALT 3xULN but <5xULN and cannot be monitored weekly for >4 weeks', 'Symptomatic\u00b3', 'ALT > 3xULN associated with symptoms (new or worsening) believed to be', 'related to liver injury or hypersensitivity', 'Required Actions and Follow up Assessments following ANY Liver Stopping Event', 'Actions', 'Follow Up Assessments', 'Immediately discontinue study treatment', 'Viral hepatitis serology4', 'Report the event to GSK within 24 hours', 'Only in those with underlying chronic', 'Complete the liver event CRF and complete', 'hepatitis B at study entry (identified by', 'an SAE data collection tool if the event also', 'positive hepatitis B surface antigen)', 'meets the criteria for an SAE\u00b2', 'quantitative hepatitis B DNA and hepatitis', 'delta antibody5.', 'Perform liver event follow up assessments', 'Blood sample for pharmacokinetic (PK)', 'Monitor the subject until liver chemistries', 'analysis, obtained within a week after last', 'resolve stabilize, or return to within normal', 'dose6', 'ranges. baseline (see MONITORING below)', 'Serum creatine phosphokinase (CPK) and', 'Do not restart/rechallenge subject with', 'lactate dehydrogenase (LDH).', 'study treatment. Permanently discontinue', 'Fractionate bilirubin, if total', 'study treatment and may continue subject', 'bilirubin>2xULN', 'in the study for any protocol specified follow', 'up assessments', 'Obtain complete blood count with', 'differential to assess eosinophilia', 'Record the appearance or worsening of', 'clinical symptoms of liver injury, or', '70']['2016N277425_0', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Liver Chemistry Stopping Criteria - Liver Stopping Event', 'MONITORING:', 'hypersensitivity, on the AE report form', 'For bilirubin or INR criteria:', 'Record use of concomitant medications on', 'Repeat liver chemistries (include ALT, AST,', 'the concomitant medications report form', 'alkaline phosphatase, bilirubin) and perform', 'including acetaminophen, herbal', 'liver event follow up assessments within 24', 'remedies, other over the counter', 'medications.', 'hrs', 'Record alcohol use on the liver event', 'Monitor subjects twice weekly until liver', 'chemistries resolve, stabilize or return to', 'alcohol intake case report form', 'within normal ranges.', 'A specialist or hepatology consultation is', 'For bilirubin or INR criteria:', 'recommended', 'Anti-nuclear antibody, anti-smooth muscle', 'For All other criteria:', 'antibody, Type 1 anti-liver kidney', 'microsomal antibodies, and quantitative', 'Repeat liver chemistries (include ALT, AST,', 'total immunoglobulin G (lgG or gamma', 'alkaline phosphatase, bilirubin) and perform', 'globulins).', 'liver event follow up assessments within 24-', '72 hrs', 'Serum acetaminophen adduct HPLC', 'assay (quantifies potential acetaminophen', 'Monitor subjects weekly until liver', 'contribution to liver injury in subjects with', 'chemistries resolve, stabilize or return to', 'definite or likely acetaminophen use in the', 'within normal ranges.', 'preceding week [James, 2009]). NOTE:', 'not required in China', 'Liver imaging (ultrasound, magnetic', 'resonance, or computerised tomography)', 'and /or liver biopsy to evaluate liver', 'disease; complete Liver Imaging and/or', 'Liver Biopsy CRF forms.', '1.', 'Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not', 'immediately available, discontinue study treatment for that subject if ALT 3xULN and bilirubin 2xULN.', 'Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary', 'bilirubin on dipstick, indicating direct bilirubin elevations and suggesting liver injury.', '2.', 'All events of ALT > 3xULN and bilirubin > 2xULN (>35% direct bilirubin) or ALT 3xULN and INR>1.5, if INR', \"measured which may indicate severe liver injury (possible 'Hy's Law'), must be reported as an SAE (excluding\", 'studies of hepatic impairment or cirrhosis); INR measurement is not required and the threshold value stated', 'will not apply to subjects receiving anticoagulants', '3.', 'New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper', 'quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or', 'eosinophilia)', '4.', 'Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C', 'RNA; Cytomegalovirus IgM antibody; Epstein-Barr viral capsid antigen IgM antibody (or if unavailable, obtain', 'heterophile antibody or monospot testing); Hepatitis E IgM antibody', '5.', 'If hepatitis delta antibody assay cannot be performed, it can be replaced with a PCR of hepatitis D RNA virus', '(where needed) [Le Gal, 2005].', '6.', 'PK sample may not be required for subjects known to be receiving placebo or non-GSK comparator treatments.', 'Record the date/time of the PK blood sample draw and the date/time of the last dose of study treatment prior to', \"blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the subject's best\", '71']\n\n###\n\n", "completion": "END"}